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Introduction
The novel coronavirus that has recently emerged in Wuhan, China with probable bat
origin is part of the betacoronavirus family which is similar to previously seen zoonotic based out
breaks in the early 2000’s with SARS as well as in 2012 with MERS1. COVID-19 is the disease
obtained from being infected by the novel SARS-CoV-2 virus, which enters through ACE2
(angiotensin-converting enzyme 2) cell receptors which is similar to SARS-CoV and MERS-CoV
uses the DDP4 (dipeptidyl peptidase 4) cell receptor1. SARS-CoV-2 shares approximately 80% of
its genomic identity with SARS-CoV2. Currently, there is a lot research being conducted to
understand how SARS-CoV-2 infects humans to be able to develop drugs and therapy options to
treat the virus as well as produce a vaccine to protect the global population from becoming
infected. Understanding how SAR-CoV-2 enters cells will be able to provide important
information for vaccine designs and drug targets1. There are four main categories for therapies
to treat viral drugs depending on the activity, which are: preventing the viral RNA synthesis and
replication, blocking the virus from binding to human cell receptors, restoring the host’s innate
immunity, and blocking host’s specific receptors or enzymes2. This review discusses current
nonspecific antiviral drugs that are being explored for potential treatments, potential
biotherapeutic and small molecule drug candidates, use of convalescent plasma and monoclonal
antibodies as other therapies, and explore possible drug targets and computational studies
currently in progress to able to develop specific antiviral drugs and vaccines.
1. Repurposing of Generic Antiviral Drugs to Treat COVID-19
Since there are no drugs or treatments currently available to specifically treat COVID-19,
there are clinical trials being conducted using general antiviral drugs until a vaccine or drugs can
be developed. Additionally, since all current drug options are currently undergoing clinical trials,
there is no proven effective treatment for COVID-193.
Lipinavir-Ritonavir
As reported in the New England Journal of Medicine by Cao et al., a trial was conducted of
Lopinavir-Ritonavir in adults that are hospitalized with severe COVID-193. A randomized,
controlled, open-label trial was conducted with hospitalized adult patients with confirmed SARSCoV-2 infections3. These patients were either given lopinavir-ritonavir twice a day for 14 days
along with standard care, or standard care alone with the primary goal of clinical improvement3.
The authors saw that there was no significant improvement with this drug combination
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compared to standard care as the time for clinical improvement was only shortened by 1 day 3.
The observed gastrointestinal adverse events were more common in the lopinavir-ritonavir
group, but they found more serious adverse events were more common in the standard-care
group3. Lopinavir is an aspartate protease inhibitor used to treat HIV type 1 infections and was
shown to have inhibitory activity against SARS-CoV3. Ritonavir, when combined with Lopinavir
can increase its plasma half-life through the inhibition of cytochrome P4503. This drug
combination was used in a study in 2004 to treat patients with SARS and that along with ribavirin,
was able to reduce the risk of adverse clinical outcomes as well as reduce the viral load3. This
drug combination has also shown similar results in vitro studies and animal models for MERS-CoV
and suggest that lopinavir-ritonavir with ribavirin and interferon alpha could result in virologic
clearance and survival3. This trial only consisted of a total of 199 patients between the two
groups3 and it would be interesting to see a similar trial conducted on a larger scale to see if this
drug combination could be successful to treat SARS-CoV-2.
Chloroquine and Remdesivir
Multiple clinical trials are currently being conducted so show that Chloroquine can be
used as an effective treatment for COVID-19. In the review article by Cortegiani et al, they report
that there are 23 ongoing clinical trials in China that shows Chloroquine is effective in limiting the
replication of SARS-CoV-2 in vitro4. Chloroquine is an immunomodulant drug traditionally used
to treat malaria, but in vitro studies show that it is effective in reducing the viral replication in
other infections such as SARS-CoV and MERS-CoV4. Although the World Health Organization
(WHO) list Chloroquine as an essential medicine, the efficacy and safety of Chloroquine for the
treatment of SARS-CoV-2 pneumonia remains unclear4. They report a narrative letter from a
news briefing from the State Council of China that indicates Chloroquine phosphate has
demonstrated marked efficacy and acceptable safety in treating COVID-19 associated pneumonia
in multicenter clinical trials conducted in China5, but evidence of this data has not been found4.
They also reported that an expert consensus reported that a Chloroquine phosphate dose of 500
mg twice a day for ten days is recommended for patients with cases of SARS-CoV-2 pneumonia,
but with several precautions to prevent possible side effects, but this report was based on in vitro
evidence and is still unpublished4. Currently there are multiple ongoing trials in China to prove
the efficacy of Chloroquine as a potential treatment of SARS-CoV-2, but no published data is
available yet4. There will be more data released on this topic once more information from the
clinical trials is released4. Early in vitro studies showed that Chloroquine was found to block
COVID-19 infection at a low micromolar concentration with a half-maximal effective
concentration of 1.13µm5. Multiple clinical trials are being conducted in China to show the
efficacy of chloroquine and hydroxychloroquine for treatment of COVID-19 associated
pneumonia in more than 100 pateints5. The results show that chloroquine phosphate is superior
to control the treatment in inhibiting the exacerbation of pneumonia, improving lung imaging,
promoting a virus-negative conversion and shortening the disease according to a news briefing
form China5. Studies has shown that Chloroquine has potential for broad spectrum antiviral
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activity by increasing endosomal pH required for virus/cell fusion, as well as interfering with the
glycosylation of cellular receptors of SARS-COV5,6. In a study by M. Wang et al, they show that
besides antiviral activity, chloroquine also has immune-modulating activity, which could
synergistically enhance its antiviral effect in vivo and is also distributed in the whole body
including the lungs after oral adminiatration6.
In a letter to the editor published in Cell Research by M. Wang et al., they stress the need
to urgently identify effective antiviral agents for treating COVID-19 is needed and suggest the
most efficient approach is to test existing antiviral drugs that are effective in treating related viral
infections6. This novel viral infection falls under the β-Coronavirus family, which also includes
SARS-CoV and MERS-CoV6. To treat these infections in the past, antiviral drugs such as ribavirin,
interferon, lopinavir-ritonavir, and corticosteroids were used, but the efficacy of some drugs
remains controversial6. The authors studied 5 FDA approved drugs including ribavirin, penciclovir,
nitazoxanide, nafamostat, chloroquine, and two broad spectrum antiviral drugs remdesivir and
favipiravir in an in vitro study with a clinical isolate of SARS-COV-26. The authors conducted
standard assays to measure the effects of these compounds on the cytotoxicity, virus yield and
infection rates for the COVID-19 in Vero E6 cells6. They found that ribavirin, penciclovir, and
favipiravir were required to reduce the viral infection6. They also found that Nafamostat, which
is a potent inhibitor for MERS-CoV was inhibitive against COVID-19 infection6. Nitazoxanide,
which is a commercial antiprotozoal agent with antiviral potential was able to inhibit COVID-19
as a low-micromolar concentration6. Two possible drug options, remdesivir and chloroquine
were able to potently block virus infection at a low-micromolar concentration6. The authors
suggest that remdesivir and chloroquine are effective to control COVID-19 infection in vitro and
since there is previous data on the safety of the drugs in humans, it suggested that they be
assessed in humans to treat COVID-196.
Remdesivir is a promising antiviral drug against a wide array of RNA virus infections in
cultured cells, mice and nonhuman primate models6 and is currently under clinical development
for the treatment of Ebola6. This adenosine nucleoside analog acts as an RdRp (RNA-dependant
RNA polyermase) inhibitor that targets the viral genome replication process6,7. The host will
metabolize the drug into NTP which competes with ATP to incorporate into the nascent RNA
strand7. Once the substitution occurs, the new strand will result in premature termination of RNA
synthesis6,7. The benefit of remdesivir is that it will outpace the proofreading activity that many
coronaviruses possess to be able to detect and remove other nucleoside analogs. This takes away
the activity that makes the viruses resistant to many RNA based antiviral drugs7. Currently, there
are multiple-site clinical trials in progress to treat SARS-CoV-2 in hospitalized adults using
remdesivir that are a result of in vitro and in vivo studies on similar coronaviruses7. Studies have
been done on SARS-CoV and MERS-CoV using human epithelial cell cultures and found that
remdesivir had strong antiviral activity against MERS-CoV7. The use of remdesivir was first
reported to treat COVID-19 in humans on the first infected patient in the US after developing
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pneumonia and being hospitalized for more than 12 days7. Intravenous remdesivir was used on
the seventh day and by the eighth day, his condition was improving, and no adverse effects
related to remdesivir were reported7. There have been other reports of remdesivir being used
on humans outside the clinical trials. As reported in the review by E. Amirian and J. Levy, a
newspaper article reported that 17 passengers on the Diamond Princess cruise ship were treated
with remdesivir for 10 days and the doctors felt the patients were less dependent on ventilators7.
There are multiple clinical trials currently in progress in the US, Republic of Korea, and China, as
well as a sponsored study by Gilead Sciences in which patients with different severities of COVID19 receive the drug or placebos and to see how they improve overtime based a scale from death
to no longer hospitalized7.
Drug Combinations and Antibiotics for Treating COVID-19
Additionally, there are other reports of potential drug combination to treat SARS-CoV-2,
but more information and testing will be needed to show the efficacy of these drug combinations.
In an article by Gautret et al., they report the findings of a non-randomized clinical trial of
hydroxychloroquine and azithromycin to treat COVID-198. In this French study, patients with
confirmed cases were treated with 600 mg of hydroxychloroquine daily and their viral loads
tested daily by nasopharyngeal swabs and the addition of azithromycin was added to the
treatment depending on the clinical presentation8. Day 6 was considered the end point of the
study and looking at the presence or absence of the virus8. The negative control group consisted
of untreated patients from another center or patients who refused the protocol 8. The authors
found that there was a significant reduction in viral carriage compared to the controls and the
addition of azithromycin was significantly more efficient for virus elimination8. They found that
100% of the patients who received the drug combination were cleared after 6 days compared to
57.1% of patients treated with only hydroxychloroquine and 12.5% in the control group 8. The
authors report that there has been previous data to show that azithromycin is active against ZIKA
and Ebola viruses as well as to prevent severe respiratory tract infections in patients suffering
viral infections8. There were only 20 cases treated in this study with an additional 16 patients in
the control group8 and it would be interesting to see the results of this trial with a larger
population. If these results are repeatable, this drug combination could be useful in the fight
against COVID-19 as the added use of an antibiotic will also be able to fight possible
superinfections8.
In an article by Stebbing et al., they discuss the use of artificial intelligence to look at
potential combinations of anti-inflammatory drugs with anti-viral drugs could be used to treat
COVID-199. The authors are suggesting that anti-inflammatory drugs that inhibit clathrinmediated endocytosis could inhibit viral infections in cells9. They suggest that the potential drug
targets are members of the numb-associated kinase (NAK) family, which includes AAK1 and GAK
have been shown to inhibit viral infections in vitro9. They further suggest that this drug family
along with potential anti-viral drugs such as lopinavir-ritonavir and remdesivir could be effective
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to treat COVID-19 by reducing viral infectivity, viral replication, and aberrant host inflammatory
response9. Since this study was based on data collected from artificial intelligence, it would be
interesting to see results of cell studies and potential animal studies on these drug combinations
to see if they work. Additionally, if this combination shows successful results from in vitro and
animal studies, it would be interesting to see results in clinical studies in humans. Like most drug
candidates and combinations of drugs currently being explored to treat COVID-19, the drugs
being proposed are safe and approved for treatment of other diseases. Teicoplanin is a
glycopeptide antibiotic that is typically used to treat gram-positive bacterial infections such as
staphylococcal infections but has also shown to inhibit the first stage of MERS-CoV viral life cycle
in human cells as well as being active against SARS-CoV in vitro10. It has already shown to be
effective against Ebola, influenza, flavivirus, hepatitis C, HIV, and MERS-CoV and SARS-CoV
viruses10. Teicoplanin is effective in coronaviruses by acting on the early stage of the viral life
cycle by inhibiting the low-pH cleavage of the viral spike protein by cathepsin L in late endosomes
and preventing the release of genomic viral RNA and the continuation of the replication cycle 10.
As this is shown to have promising results in related coronaviruses, there is a potential that it can
have a similar effect on SARS-CoV-2.
2. Potential Biotherapeutics and Small Molecule Drug Candidates
Research into the spike proteins suggests that there is 89.8% sequence homology
between SARS-CoV and SARS-CoV-2 in the S2 subunit of their spike proteins while their S1
subunits use hACE2 to infect human cells11. Additionally, the ACE2 binding affinity in the receptor
binding domain in the S1 subunit of SARS-CoV-2 is much higher than SARS-CoV, which may
contribute to the higher affinity and transmissibility of SARS-CoV-211. Research by Xia et al.
suggests that by conjugating a cholesterol molecule to an EK1 peptide, they were able to show
that this lipopeptide, EK1C4 was able to exhibit a highly potent inhibitory activity against SARSCoV-2 S-mediated membrane fusion and PsV infection11. The EK1 peptide was previously
developed by the authors and is a pan-coronavirus inhibitor that targets the HR1 domain11. They
also found that the EK1C4 peptide was effective against in vitro and in vivo infections for other
live coronaviruses such as SARS-CoV-2, HCoV-OC43, and MERS-CoV which could suggest the
development of a further inhibitor based therapeutic and prophylactics for other coronavirus
based infections11.
In a paper by Sheahan et al., they report that the ribonucleoside analog, β-D-N4hydroxycytidine had broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, and SARSCoV12. β-D-N4-hydroxycytidine is an orally bioavailable ribonucleoside analog that has broad
spectrum antiviral activity against various RNA viruses such as influenza, ebola, CoV, and
Venezuelan equine encephalitis12. The authors preformed antiviral assays in cells lines with
MERS-CoV and SARS-CoV-2 to see if β-D-N4-hydroxycytidine will block replication of the virus12.
First, they tested the antiviral activity for β-D-N4-hydroxycytidine against MERS-CoV in the human
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epithelial cell line Calu-3 2B4, by testing the virus replication after the cell cultures were exposed
to the virus and then exposed to a dose range of drugs for 48 hours 12. They found β-D-N4hydroxycytidine had highly potent antiviral activity with an average half-maximum effective
concentration of 0.15µM and did not observe any cytotoxicity in similarly treated uninfected
cultures12. Then they performed antiviral assays of SARS-CoV-2 with African green monkey kidney
cells and found that β-D-N4-hydroxycytidine was highly potent as well with an average halfmaximum effective concentration of 0.3µM12. Then they determined the antiviral activity of β-DN4-hydroxycytidine on SARS-CoV-2 in human epithelial cell line Calu-3 2B4 cells through the
measurement of infectious virus production and viral genomes12. They observed a dosedependent reduction in virus titers and an average half-maximum effective concentration of
0.08µM12. They tested the antiviral activity of β-D-N4-hydroxycytidine against both viruses in
primary airway epithelial cell cultures and observed a does dependent reduction of in SARS-CoV2 infectious virus production and a substantially reduced virus production in MERS-CoV12. The
authors mention that their study lacks in vivo efficacy testing with SARS-CoV-2 due to robust
mouse models that recapitulate SARS-CoV-2 pathogenesis observed in humans does not exist
since a noted spike glycoprotein and mouse ACE2 receptor are incompatible and suggest β-D-N4hydroxycytidine should be evaluated in primate models12.
3. Computational and Binding Studies to Develop Drug Targets and Potential Drug Candidates
In addition to repurposing antiviral drugs, there on-going research into characterizing
SARS-CoV-2, with the goal to develop specific antiviral drugs and possible vaccine candidates.
There is not a lot data published for potential antiviral drugs or vaccines candidate at this time
since this is still a relatively novel virus and we are still learning new information about the virus
every day. There have been some articles published using docking studies and other
computational techniques to probe potential therapeutic targets. Understanding the main
binding targets of SARS-Cov-2 can help develop the next generation of targeted drugs and
effective vaccines.
A research article by C. Wu et al. , used computational methods to analyze therapeutic
targets for SARS-CoV-2 and potential drugs13. The goal of their study was to provide new lead
compounds and targets for further in vitro and in vivo studies, as well as new insights into the
drugs currently being used in clinical trials and discover potential new strategies for drug
repurposing for SARS-CoV-2 infections13. The authors analyzed all the proteins encoded by SARSCoV-2 genes and compared them with proteins from other coronaviruses and predicted their
structures to build 19 structures by homology modeling13. They performed a target-based virtual
ligand screening, where a total of 21 targets were screened against ZINC drug database and the
author’s own database of natural products13. The results of the screen showed that the important
targets were 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase
(RdRp), and papain like protease (PLpro) for the development of coronavirus drugs 13. The
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authors also screened a database of 78 commonly used anti-viral drugs including those on the
market as well as undergoing clinical trials for SARS-CoV-213. They were able to predict possible
targets of these compounds and potential for drugs to act on certain targets 13. Based on their
targets, they were able to find multiple small molecules and natural products for each target that
are approved for use in treating many other diseases13. Targeting spike proteins or other specific
receptors on the host cell surface is valuable for developing therapeutic strategies to block
coronaviruses from entering host cells13. The authors also looked at the binding interface of
Spike-ACE2 complex and found that hesperidin was the only compound that was able to target
the binding interface13. Additionally, the authors looked at 78 commonly used antiviral drugs and
found that remdesivir seemed to be the best at binding to RdRp of SARS-CoV-2 as a possible
treatment for COVID-1913 as described earlier in this review. Another potential drug candidate is
lopinavir and ritonavir and was found to have a poor effect on the treatment of SARS-CoV-2
pneumonia with toxic side effects, but the authors did not observe any potential binding sites to
the major targets suggesting that this it may not be a suitable treatment for COVID-1913.
Chloroquine phosphate has been showing positive outcomes in clinical trials to treat COVD-19,
but there seems to be no clear target of action13. The docking studies predict that chloroquine
may combine with Nsp3b and E-channel, but further experiments are needed to verify13. Other
drugs such as arbidol which treats upper respiratory tract infections caused by influenza A and B,
darunavir which is an HIV-1 protease inhibitor, favipiravir which is used to treat the flu, and many
other possible drugs were explored and interacted with some of the important targets, but were
not discussed further in this paper13.
The S protein plays the most important roles in viral attachment, fusion, entry and serves
as a target for the development of antibodies, entry inhibitors, and vacines14. The S protein
mediates viral entry into host cells by binding to a host receptor and the receptor-binding domain
(RBD) in the S1 subunit and fusing the viral and host membranes through the S2 subunit 14. It is
reported that the SARS-CoV-2 S protein binds the ACE2 receptors in the host cell, making it critical
to define the RBD in SARS-CoV-2 S protein as the most possible target to develop virus
attachment inhibitors, neutralizing antibodies, and vaccines14. In a study by W. Tai et al., they
identified the RBD fragment in SARS-CoV-2 S protein to be able to use the region to develop a
viral attachment inhibitor and vaccine14. They found that using a recombinant RBD protein will
bind strongly to ACE2 receptors and blocked the entry of SARS-CoV-2 in hACE2- expressing cells14.
This suggest that a SARS-CoV-2 RBD protein could be used as a viral attachment or entry inhibitor
against SARS-CoV-214. Further studies could be conducted to carry out the development of this
protein for in vitro, and animal studies in the lab.
As reported in ACS NANO by Y. Han and P. Kral, they performed computation studies to
develop ACE2 based peptide inhibitors of SARS-CoV-22. The inhibitors were formed by two
sequential self-supporting α-helices that were extracted from the protease domain of ACE22.
Molecular dynamics simulations show that the α-helical peptides maintain their secondary
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structure and provide a highly specific and stable binding to SARS-CoV-22. The α1,2-helices
extracted from ACE2 are shown to support each other and maintain their bent shape which is
important as it provides a conformational matching to the RBD of SARS-CoV-2 and fully covers
the RBD surface was observed in theses computational studies2. The authors suggest that the
binding affinity could be further enhanced by binding multiple peptides to surfaces of
nanoparticles, dendrimers, and clusters, which could be turned into inhaled therapeutics
preventing the virus activation in lungs2. Further studies could be conducted to carry out the
development of these peptides for in vitro, and animal studies in the lab.
4. Treating COVID-19 by Antibodies and Immunotherapeutic Approaches
In addition to looking at potential drug options, there is an ongoing discussion about using
monoclonal antibodies to treat COVID-19. Monoclonal antibodies represent a major class of
biotherapeutics for passive immunotherapy to fight against viral infections 15. Using passive
immunotherapy can be used to reduce virus replication and decrease the severity of the illness15.
These antibodies can be isolated from the blood of infected patients or manufactured in the lab 15.
In recent years, monoclonal antibodies have been developed for use against viruses and many
are currently in clinical development15. Some potential specific therapeutic molecules could
include peptidic fusion inhibitors, anti-SARS-CoV-2 neutralizing monoclonal antibodies, anti-ACE2
monoclonal antibodies, and protease inhibitors15. It is being suggested that targeting the RBD of
the S1 subunit of the spike protein that interacts with the ACE2 receptor is a potentially effective
therapeutic against SARS-COV-2 infection15. It has been reported that monoclonal antibodies
targeting spike proteins in SARS-CoV and MERS-CoV showed promising results in vitro and in vivo
that may be effective for SARS-CoV-215. Using monoclonal antibody cocktails may provide more
potent anti-virus activity and could be a more effective treatment since the combination of
antibodies would neutralize a wide range of isolates including escaped mutants15. Although this
is promising, one of the challenges is the time and cost for large scale production of monoclonal
antibodies which outweighs the clinical application especially with emerging pathogens15.
Another Immunotherapeutic approach being explored is the use of convalescent sera or
plasma transfer to infected patients to help neutralize viruses and prevent further infection15.
There is existing evidence that suggests treating viral infections such as influenza, SARS, MERS,
and Ebola with convalescent plasma or hyper-immune immunoglobulin from patients that
contain significant antibody titers can reduce the viral load and disease mortality15. A small study
was conducted by K. Duan et al. on 10 patients that were hospitalized with COVID-19 and were
treated with convalescent plasma (CP) from recently recovered donors that had neutralizing
antibody titers above 1:640 in addition to receiving supportive care and antiviral agents16. They
were able to find that the viral load was undetectable after transfusion in 7 patients who
previously had viremia with no adverse effects observed16. Based on their preliminary results, CP
26

Seton Hall Biochemistry II Annals of Student Reviews
Vol 1. No. 4
2020

therapy was found to be easily accessible, promising, and a safe rescue options for patients with
severe COVID-1916. The authors were able to show that one dose of CP with a high concentration
of neutralizing antibodies can rapidly reduce the viral load and improve clinical outcomes 16.
Besides the study have a small sample size, all the patients in the study received antiviral
treatments as well as supportive care so it is not clear how these treatments worked together or
if CP therapy alone is enough to treat COVID-1916. A similar study by B. Zhang et al. was also
conducted with 4 patients with severe cases of COVID-19 and received CP therapy along with
supportive care with similar results17. A clinical study should be conducted of CP alone to test the
efficacy of this therapeutic approach as suggested by the authors from both paper16,17. Some key
clinical challenges with this approach are the availability of sufficient donors, clinical conditions,
viral kinetics, and hoist interactions of SARS-CoV-2 need to be explored before use as a possible
therapeutic15.
Drug Category

Therapy/Drug

β-D-N4-hydroxycytidine
Lipinavir-Ritonavir
Chloroquine
preventing viral RNA synthesis and replication Remdesivir
hydroxychloroquine and azithromycin
anti-inflammatory drugs with anti-viral drugs
Teicoplanin
SARS-CoV-2 recombinatn RBD protein
blocking the virus from binding to human cell ACE2 based peptide inhibitor
receptor
Hesperidin
lipopeptide EK1C4
Vaccines
restoring the host's innate immunity
Convalescent Plasma
Monoclonal Antibodies
blocking the host's specific receptor or Vaccines
enzymes
Monoclonal Antibodies
Table 1. Summary of Potential Drug Candidates to Treat COVID-19.

Conclusions
There are multiple articles that stress that there are no drugs or treatments specifically
available to treat SARS-CoV-2 and there is no proven effective treatment since the virus has
recently emerged in late 2019. Currently, there are multiple clinical trials in progress for
repurposing potential generic antiviral drugs such as chloroquine, remdesivir, lopinavir-ritonavir,
and other drugs to treat the symptoms for individuals who are currently infected. At this time,
there is very little data to show that these antiviral drugs can effectively treat COVID-19, but this
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is due to the fact that clinical trials are currently in progress and premature publication of results
could lead to serious outcomes for future patients. From the data that was found, the clinical
trials seemed to have small sample sizes and were specific to select regions. It would be
important to see larger sample populations from different regions to be able to understand the
outcome of the drugs on treating the virus. There are multiple factors that can affect the outcome
of the disease and how these antiviral drugs might work including individual’s location, severity
of the infection, underlying conditions and other medications which means more than one drug
will be important to fight this infection.
In addition to using these generic antiviral drugs, the use of convalescent plasma from
recovered patients seems like this would help to improve the ability for infected individuals to
generate an immune response to fight the disease which seems like best approach that has been
reported to date. Since there are over a million cases globally to date, there should be more
access to convalescent plasma from recovered patients to treat the virus. More research can be
done to investigate this immunotherapeutic treatment to see if this is this is the best approach
to fight the disease.
The research into the characterization of the structure and function of SARS-CoV-2 is still
on going and there are computational studies in progress to determine potential targets for the
development on specific antiviral drugs and vaccines. As COVID-19 has become a global pandemic
with millions infected and thousands dying, there is a need to produce a vaccine to stop the
spread of infection. This will take some time as development, testing, and trials are needed to
make sure that potential vaccines are safe and will work effectively in humans as well as
manufacturing on a large scale will be needed to protect the global population from this disease.
Since SARS-CoV-2 has emerged within the past 5-6 months, it is still very early and there is still
more research and knowledge to be acquired about the virus. Continuing to work to develop
specific drugs and vaccines as well as the effectiveness of the general antiviral drugs on the virus
is important, but it will still take a long time to accomplish these tasks.
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